This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
France
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.
Adocia is specialized in insulin therapy and the treatment of diabetic foot, one of the main complications of diabetes.
Through its BioChaperone state-of-art technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicine accessible to the broadest public.
Adocia is specialized in insulin therapy and the treatment of diabetic foot, one of the main complications of diabetes.
Through its BioChaperone state-of-art technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicine accessible to the broadest public.
Advicenne Pharma is a biopharmaceutical company dedicated to Paediatry.. Company's lead candidate ADV6209 is an innovative liquid formulation of a benzodiazepine specifically developed for oral administration for moderate sedation and anesthetic premedication.
Affichem is a medical biotechnology company whose mission is to design, develop and market innovative therapeutic molecules and theranostic markers for the treatment of cancer and neurodegenerative diseases. Company's lead candidate AF122 : is an anti-cancer drug against Acute Myelogenous Leukemia.
Affilogic is a biotech company established in Nantes and developing a new class of proprietary affinity ligands : Nanofitins
AISA Therapeutics is focused on the research and development of new anti-inflammatory / anti-senescence molecules as an alternative to steroidal and non-steroidal anti-inflammatory drugs and the side effects of anti-TNF drugs.
Alaxia develops novel medicinal products for respiratory diseases like Cystic Fibrosis, Inflammation, sore throat, sinusitis etc. based on their peroxidase platform. Meveol product is in development to treat cystic fibrosis.
Alfact Innovation is a biotechnology company focused on the discovery and the development of biopharmaceuticals to provide innovative therapies in hepatology and oncology disorders. Their
lead program, ALF-5755 is a recombinant protein of the secreted human protein HIP/PAP.
lead program, ALF-5755 is a recombinant protein of the secreted human protein HIP/PAP.
ALGENICS is a biopharmaceutical company leveraging a unique microalgae-based technology to produce recombinant therapeutics for animal and human health. Company's proprietary platform Algebiosys? encompasses tools and technologies specifically developed to ensure both stable genetic transformation of our cell line and high expression level of recombinant proteins based on proprietary vectors and genetic regulatory elements.
Alienor Farma specializes in development of drugs for the treatment of rare diseases. Company's R & D program is based on cancer treatment, antiretroviral drugs used initially in the
treatment of AIDS.
treatment of AIDS.
Alliospharma develops and markets innovative molecules and products with evidence-based composition, bringing solutions to frequent pathological, physiological and lifestyle conditions such as imbalances of the mucous membranes, diabetes, obesity, some inflammatory illnesses.
Almetis is a french biopharmaceutical company created in 2010 and dedicated to the discovery and the development of innovative metal-based drugs in oncology. The company's expertise in organometallic compounds is unique and our objective is to develop proprietary candidates up to proof of concept in man. Their mission is to deliver a new class of drugs using the innovative properties of our compounds and addressing unmeet needs in oncology.